Rank in 2013: 12th
Community Size: 10th
Activity: 12th
Engagement: tied for 14th
Virality: 8th

AstraZeneca ($AZN) ranked last for engagement and near the bottom for activity, however, its No. 10 overall designation means it actually rose in Ogilvy's ranking by two spots this year. According to the survey, AZ is active on 6 social media sites, which is average, but is networked across only two of them, which may be part of the engagement problem. IMS Health's study on social pharmas found AZ had a low retweet rate of 2.1 per tweet.

Its Facebook page--AstraZeneca US Community Connections--focuses mainly on disease awareness and corporate initiatives, such as its Youth Health Programme, which is a common tactic among pharma. However, its Twitter feed can be more engaging and conversational, especially when the social media team tweets from conferences.

AstraZeneca also got social media props for its cancer initiative on Twitter and Instagram in October, encouraging women to share information and photos relating to their metastatic breast cancer experience, hashtagged #MBCStrength.

For more:
AstraZeneca grabs $215M for GI drug rights in latest cash-generating deal
AZ's Bydureon tops doc-payments list with $22B
AstraZeneca, Ironwood score PhIII success in China
AstraZeneca and Cephalon pony up $50M+ to settle Medicaid pricing claims
Bad news for AstraZeneca: FDA lays out roadmap for would-be Symbicort copycats


Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.